Kimberly Ann Tipton

US Patent:

20210222143, Jul 22, 2021

Filed:

Jan 3, 2020

Appl. No.:

16/734256

Inventors:

- South San Francisco CA, US
Christopher Thanos - Tiburon CA, US
Vanessa Soros - San Francisco CA, US
Mikhail Popkov - San Diego CA, US
Kimberly Tipton - Boston MA, US
Matthew John Traylor - Boulder CO, US
Eric Steven Furfine - Lincoln MA, US
Jeffrey Charles Way - Cambridge MA, US

International Classification:

C12N 9/72
C07K 14/765

Abstract:

Provided are u-PA polypeptides and fusion proteins containing the u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.

US Patent:

20200216463, Jul 9, 2020

Filed:

Sep 19, 2018

Appl. No.:

16/648991

Inventors:

Vasu JAMMALAMADAKA - Dublin CA, US
Kimberly Ann TIPTON - San Francisco CA, US
Sanjeev SATYAL - San Carlos CA, US
Hoyoung HUH - Portola Valley CA, US
- Seoul Jongno-Gu, KR

Assignee:

pH Pharma Co., Ltd. - Seoul

International Classification:

C07D 493/10
A61K 47/68
A61P 35/00

Abstract:

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

US Patent:

20190233430, Aug 1, 2019

Filed:

Apr 5, 2019

Appl. No.:

16/376540

Inventors:

- Seoul, KR
Kimberly Ann Tipton - San Francisco CA, US
Sanjeev Satyal - San Carlos CA, US
Hoyoung Huh - Portola Valley CA, US

Assignee:

pH Pharma Co., Ltd. - Seoul

International Classification:

C07D 493/10
A61P 35/00
C07D 493/04
A61K 45/06
A61K 47/68

Abstract:

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

US Patent:

20190202927, Jul 4, 2019

Filed:

Nov 13, 2018

Appl. No.:

16/189777

Inventors:

- South San Francisco CA, US
Kimberly Ann Tipton - San Francisco CA, US
Jonathan Alexander Terrett - Lexington MA, US
Shweta Singh - Fremont CA, US
Annie Yang Weaver - San Mateo CA, US
Luc Roland Desnoyers - San Francisco CA, US

International Classification:

C07K 16/28
A61K 39/395
C07K 16/30
A61K 47/68
A61P 35/00
A61K 49/00

Abstract:

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

US Patent:

20190084996, Mar 21, 2019

Filed:

Sep 19, 2018

Appl. No.:

16/135287

Inventors:

- Seoul, KR
Kimberly Ann Tipton - San Francisco CA, US
Sanjeev Satyal - San Carlos CA, US
Hoyoung Huh - Portola Valley CA, US

International Classification:

C07D 493/10
A61P 35/00
A61K 47/68
A61K 45/06

Abstract:

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

US Patent:

20160355599, Dec 8, 2016

Filed:

May 4, 2016

Appl. No.:

15/146294

Inventors:

- South San Francisco CA, US
Kimberly Ann Tipton - San Francisco CA, US
Jonathan Alexander Terrett - Cupertino CA, US
Shweta Singh - Fremont CA, US
Annie Yang Weaver - San Mateo CA, US
Luc Roland Desnoyers - San Francisco CA, US

International Classification:

C07K 16/28
A61K 39/395
A61K 49/00
A61K 47/48

Abstract:

The invention relates generally to antibodies that bind CD71, activatable antibodies that specifically bind to CD71 and methods of making and using these anti-CD71 antibodies and anti-CD71 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.